6998 — Edding Genor group Share News
0.000.00%
Last trade - 00:00- HK$3.20bn
- HK$3.52bn
- CNY2.49bn
China's Genor Biopharma soars most on record on deal to jointly develop mRNA products
Brief: Jhbp Cy - Entered Into Cooperative Development Agreement With Suzhou Abogen Biosciences
Brief: JHBP CY Says Obtained Investigational New Drug Approval From National Medical Products Administration
Brief: Jhbp Cy Says NMPA Grants New Approval For Phase I/Ii Clinical Trials Of Gb261 (Cd20/Cd3 Bsab)
Brief: Jhbp Cy Says Zhou Joe Xin Hua Tendered His Resignation As Executive Director
Brief: Jhbp Cy Posts Loss For Year RMB865.4 Mln
Brief: Jhbp Cy Says Infliximab Got Approval From China's Nmpa For Treatment Of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Among Others
Brief: Jhbp Cy Says Guo Feng Appointed As Chairman
Brief: JHBP Cy Posts HY Loss Attributable RMB400.9 Mln Vs Loss Of RMB533.4 Mln
Brief: JHBP CY Received Investigational New Drug Approval For Gb492 By NMPA
Brief: JHBP CY Holdings Posts FY Total Comprehensive Loss RMB3,032.8 Mln
Brief: Jhbp Cy Says NMPA Approves Investigational NDA For Two Gb491 (Lerociclib) Bridging Studies
Brief: JHBP CY Says NMPA Accepts New Drug Application For GB242
Chinese biopharmaceutical group JHBP shines in Hong Kong debut